BRAK LABS Peptide research, plainly written

NOTHING FOR SALE · EVERY CLAIM GRADED

A peptide reference with receipts.

Every claim on every compound page carries an evidence grade, from human trials down to anecdote. We don't sell anything, so we don't need any claim to be true.

Click any node to name the compound it carries.

field compounds · links · 0 opened

“We report what has been documented. We do not prescribe what should be done.”

The editorial policy, in one line

coverage

Four groups, covered in the depth each one earns

Every compound answers the same four questions: what it is, what was studied, what the study actually showed, and where the regulator stands today. How much space it gets varies. Coverage is tiered rather than uniform, so a compound gets its own address where there is enough sourced material to make that page worth landing on, and a substantial entry inside its category page where there is not. A letter grade appears only where this site has run its own source review, which is 2 compounds of 51 so far. These four groups are where the reading concentrates; the other 16 compounds are on the compound index. Nothing here tells anyone to take anything. Where a page reports the amounts used in a study, it reports them as what a study did, and no page on this site publishes an amount for a person.

MET

Metabolic

GLP-1 and amylin analogs. The only group in this category with large completed human trials behind it, and the only one where the regulator has already acted.

8 compounds

REP

Repair and recovery

Tissue-repair compounds. The best-selling group in the market and among the thinnest on human evidence, which is the single most useful fact a reader can leave with.

6 compounds

GHS

Secretagogues

Growth-hormone-releasing peptides and ghrelin-receptor agonists. Mostly studied as short endocrine experiments rather than as anything a person would use.

9 compounds

LNG

Longevity and cognitive

Bioregulators and neuropeptides. The group with the widest gap between what the marketing says and what the published research covers, which is where the grading earns its keep.

12 compounds

compounds

The index

6 shown, out of the whole category on the compound index. Each card carries the group, the evidence grade, the number of completed human trials of that compound, and the regulatory position. The grade comes before the description on purpose. 2 of them are backed by a published review, so both figures on those cards are derived from the tiers on the page they link to. The other 4 say so where a review has not been run, because a grade or a count this site has not derived is one it does not publish.

An index points at a claim, it does not make one. Where a card shows a grade its page has published, and every figure on that card is restated there with its source, and with an evidence tier wherever the figure is a claim about what the compound does rather than a regulatory or operational fact. The remaining cards carry no grade and no trial count, and the regulatory word on each is restated with its document on the entry the card links to.

evidence

How the grades work

One scale, applied the same way to every compound, published so anyone can check it. A grade describes the quality of the research, not whether something works and not whether anyone should use it. The full derivation is on the methodology page.

the gap

Completed, published human efficacy trials for BPC-157:

0

Zero, and that number is the most useful thing a reader can know about the best-selling compound in this category. Two trials are registered: a phase 1 from 2015 whose status is unknown, and a phase 2 now recruiting. Small human studies do exist outside those registrations, in groups of a few dozen people and by routes almost nobody uses, and in July 2026 FDA told its own advisory committee they were not enough to reach a conclusion on effectiveness. Past that, the record is animal studies and community reports, and that is the weight the claims made for this compound are resting on.

registered trials
2
completed and published
0
evidence grade
not reviewed yet

Counts on this page come from the public trial registries and are provisional until the BPC-157 page publishes, where each trial appears with its registry identifier, its status, and the date it was last checked. An index points at a claim, it does not make one. FDA set out its own reading of the BPC-157 record to an advisory committee in July 2026, and we have summarised what that meeting did and did not do in the 503A record.

guides

Recent guides

Every guide is dated, every claim carries a citation, and every page says who checked it. Corrections stay visible at the bottom of the page instead of being edited away. Both rows below are published, and the grade and source count on each are read from the page it links to.